摘要
目的系统评价化疗药物所致周围神经病变(chemotherapy-induced peripheral neuropathy,CIPN)的发生风险与糖尿病的相关性。方法检索Embase、PubMed、Web of Science、中国学术期刊全文数据库(CNKI)、万方数据库中关于CIPN的发生风险与糖尿病相关性的队列和病例对照研究,检索时限为建库—2017年12月31日,采用Stata 11.0软件对符合标准的研究进行Meta-分析。结果共纳入15篇文献,16项研究,3 541例患者。Meta-分析结果显示:糖尿病肿瘤患者发生CIPN的风险高于非糖尿病肿瘤患者(OR=1.65,95%CI=1.33～2.05,P=0.000)。亚组分析显示,无论在亚洲地区(OR=1.65,95%CI=1.28～2.12,P=0.000)还是非亚洲地区(OR=1.65,95%CI=1.08～2.53,P=0.020),CIPN的发生风险都与糖尿病相关。使用紫杉类药物化疗的肿瘤患者发生CIPN的风险与糖尿病显著相关(OR=1.72,95%CI=1.32～2.24,P=0.000),而使用奥沙利铂化疗的肿瘤患者发生CIPN的风险与糖尿病无明显相关性(OR=1.31,95%CI=0.83～2.05,P=0.242)。结论 CIPN的发生风险与糖尿病密切相关,糖尿病可以增加CIPN的发生风险。受纳入研究数量及质量的限制,该结论还需大规模、高质量的研究予以证实。
Objective To systematically evaluate the relevance of the risk of chemotherapy-induced peripheral neuropathy(CIPN)and diabetes.Methords Embase,PubMed,Web of Science,CNKI and WanFang databases were searched for cohort and casecontrol studies about the relevance of the risk of CIPN and diabetes from inception to December 31,2017.Stata11.0 software was used to perform Meta-analysis of the eligible studies.Results A total of 15 articles,16 studies,and 3 541 patients were included.Meta-analysis showed that the risk of CIPN was higher in cancer patients with diabetes than in those without diabetes(OR=1.65,95%CI=1.33-2.05,P=0.000).Subgroup analysis showed that the risk of CIPN was related to diabetes whether in Asian region(OR=1.65,95%CI=1.28-2.12,P=0.000)or non-Asian region(OR=1.65,95%CI=1.08-2.53,P=0.020).The risk of CIPN was significantly associated with diabetes in cancer patients who were treated with taxanes(OR=1.72,95%CI=1.32-2.24,P=0.000).However,the risk of CIPN was not significantly associated with diabetes in cancer patients who were treated with Oxaliplatin(OR=1.31,95%CI=0.83-2.05,P=0.242).Conclusions The risk of CIPN is closely related to diabetes which increases the risk of CIPN.Due to the limitation of quantity and quality of included studies,the conclusion needs to be confirmed by large-scale and high-quality researches.
作者
胜芙蓉
陈希
蔡云飞
蔡爽
SHENG Furong;CHEN Xi;CAI Yunfei;CAI Shuang(Department of Pharmacy,The First Affiliated Hospital of China Medical University,Shenyang 110001,China;School of Pharmacy,China Medical University,Shenyang 110122,China;Department of Dermatology,The First Affiliated Hospital of China Medical University,Shenyang I10001,China)
出处
《药物评价研究》
CAS
2018年第12期2333-2339,共7页
Drug Evaluation Research
基金
辽宁省科学技术计划项目(2012225107)
